

, ,	or II8I3 West 77th Street, Lenexa, KS 66214	(913) 341-8949 Fax (913) 341-6207
Requisition #: 388366	Physicial	NO PHYSICIAN
Patient Name: Natasha Gor	on Date of C	ollection: 5/25/2015
Patient Age: 41	Time of C	collection: 06:37 AM
Patient Sex: F	Print Date	e: 06/01/2015

Organic Acids Test - Nutritional and Metabolic Profile						itional and Metabolic Profile
Meta	bolic Markers in Urine	Reference Range (mmol/mol creatinine)			atient /alue	Reference Population - Females Age 13 and Over
Int	estinal Microbial Overg	rowth				
Yeast	and Fungal Markers					
1	Citramalic	5	3.6		0.57	0.57
2	5-Hydroxymethyl-2-furoic	≤	14		0.16	0.16
3	3-Oxoglutaric	≤	0.33		0.10	0.10
4	Furan-2,5-dicarboxylic	2	16		0.30	0.30
5	Furancarbonylglycine	≤	1.9		0.12	
6	Tartaric	≤	4.5		0.26	Q20
7	Arabinose	5	29	н	38	
8	Carboxycitric	5	29		4.0	4.0
9	Tricarballylic	2	0.44		0.16	- <u>(16)</u>
Bacte	erial Markers					
10	Hippuric	5	613		428	428
11	2-Hydroxyphenylacetic	0.06 -	0.66		0.36	0.30
12	4-Hydroxybenzoic	≤	1.3		0.41	
13	4-Hydroxyhippuric	0.79 -	17		4.9	4.9
14	DHPPA (Beneficial Bacteria) ≤	0.38		0.06	
Clost	ridia Bacterial Markers					
15 (C. dif	4-Hydroxyphenylacetic ficile, C. stricklandii, C. litusebu	≤ rense & others)	19	н	21	21
16 (C. sp	HPHPA orogenes, C. caloritolerans, C. b	≤ otulinum & others)	208		46	46
17 (C. dif	4-Cresol ficile)	≤	75		37	37
18 (C. str	3-Indoleacetic ricklandii, C. lituseburense, C. su	≤ ubterminale & others)	11		1.8	1.8

equisition #:	388366						Physician:	NO PHYSICIAN
Patient Name: Natasha Gordon				Date of Collection:	5/25/2015			
etabolic Marke		Reference R (mmol/mol crea		-		Patient Value	Referenc	e Population - Females Age 13 and Over
Oxalate Meta	bolites							
9 Glyceric		0.77	-	7.0		3.1		3.1
0 Glycolic		16	-	117		81		81
1 Oxalic		6.8	-	101		68		68
Glycolytic Cy	cle Metabolites	;						~
2 Lactic			≤	48		47		
3 Pyruvic			≤	9.1		3.1		3.1
Mitochondria	l Markers - Krei	bs Cycle Met	tab	olites				Ŷ
4 Succinic			≤	9.3		2.5		2.5
5 Fumaric			≤	0.94		0.17	0.17	
6 Malic		0.06	-	1.8		0.43	0.43	
7 2-Oxogluta	ic		≤	35		11		11
8 Aconitic		6.8	-	28	L	4.8	4.8	
9 Citric			≤	507		146		146
Mitochondria	al Markers - Am	ino Acid Met	tab	olites				
0 3-Methylglu	taric		≤	0.76		0.19	↓	19
1 3-Hydroxyg	lutaric		≤	6.2		3.0		3.0
2 3-Methylglu	taconic		≤	4.5		0.98	0.98	
Neurotransm	itter Metabolite	S						
henylalanine and 3 Homovanill opamine)	Tyrosine Metaboli ic (HVA)	tes 0.80	-	3.6		1.3		
	delic (VMA) nephrine)	0.46	-	3.7		1.2	1.2	
5 HVA / VMA		0.16	-	1.8		1.1		(1.1)
yptophan Metab 6 5-Hydroxyir erotonin)	olites ndoleacetic (5-HIAA	A)	≤	4.3		0.13	0.13	
7 Quinolinic		0.85	-	3.9		1.4	1.4	
8 Kynurenic		0.17	-	2.2		1.8		1.8
								· · · ·

Requis	sition #: 388366			Physician:	NO PHYSICIAN	
	t Name: Natasha Gordon			Date of Collection:	5/25/2015	
Metabolic Markers in Urine Reference Range Patient (mmol/mol creatinine) Value				Reference Population - Females Age 13 and Over		
Py	rimidine Metabolites - Folate I	Metabolism				
40	Uracil	≤ 9.7	5.1		< <u>5.1</u>	
41	Thymine	≤ 0.56	0.31		Q3>	
Ke	tone and Fatty Acid Oxidation	1				
42	3-Hydroxybutyric	≤ 3.1	0.94		94	
43	Acetoacetic	≤ 10	0	0.00		
44	4-Hydroxybutyric	≤ 4.8	1.4			
45	Ethylmalonic	0.44 - 2.8	1.4		(14)	
46	Methylsuccinic	0.10 - 2.2	0.83		0.83	
47	Adipic	0.04 - 3.8	0.85	0.85		
48	Suberic	0.18 - 2.2	1.2		(1.2)	
49	Sebacic	≤ 0.24	0.08	<	0.08	
Nu	tritional Markers					
/itam 50	in B12 Methylmalonic *	≤ 2.3	0.14	-0.14		
/itam 51	in B6 Pyridoxic (B6)	≤ 34	1.0	1.0		
/itam 52	in B5 Pantothenic (B5)	≤ 10	1.9			
/itam 53	in B2 (Riboflavin) Glutaric *	0.04 - 0.36	0.29	<u> </u>	0.29	
/itam 54	in C Ascorbic	10 - 200	L 0	0.00		
/itam 55	in Q10 (CoQ10) 3-Hydroxy-3-methylglutaric *	0.17 - 39	8.7	8.7		
Gluta 56	thione Precursor and Chelating Age N-Acetylcysteine (NAC)	nt ≤ 0.28	0.03	- 0.03		
<mark>Biot</mark> ir 57	n (Vitamin H) Methylcitric *	0.19 - 2.7	0.57	0.57		

A high value for this marker may indicate a deficiency of this vitamin. ¥

Requ	<i>isition #:</i> 388366			Physician:	NO PHYSICIAN
Patie	nt Name: Natasha Go	ordon		Date of Collection:	5/25/2015
		Reference Range (mmol/mol creatinine)	Patient Value	Reference P	Population - Females Age 13 and Over
In	dicators of Detoxificatio	n			
Sluta	athione				
58	Pyroglutamic *	10 - 3	3 14	14	
59	2-Hydroxybutyric *	0.03 - 1	8 0.43	0.43	
mn	nonia Excess			Â	
0	Orotic	0.06 - 0	54 0.17	0.17	
spa 61	artame, salicylates, or GI bact 2-Hydroxyhippuric	eria ≤ 1.	3 H 1.6		
	2-nyuroxymppune				>
*	A high value for this marker	may indicate a Glutathio	ne deficiency.		
Ar	nino Acid Metabolites				
2	2-Hydroxyisovaleric	≤ 0.	42 0	0.00	
3	2-Oxoisovaleric	≤ 2	1 0	0.00	
4	3-Methyl-2-oxovaleric	≤ 0.	87 0	0.00	
5	2-Hydroxyisocaproic	≤ 0.	48 0.08	0.08	
6	2-Oxoisocaproic	≤ 0.	37 0.09	- 0.09	
7	2-Oxo-4-methiolbutyric	≤ 0.	16 0.04		
8	Mandelic	≤ 0.	21 0.18		0.18
9	Phenyllactic	≤ 0.	20 0	0.00	
0	Phenylpyruvic	0.20 - 1	9 0.60	0.60	
1	Homogentisic	≤ 0.	36 0.28		0.28
2	4-Hydroxyphenyllactic	≤ 0.	80 0.46		0.46
3	N-Acetylaspartic	≤ 3.	0 0	0.00	
74	Malonic	≤ 9.	7 0.90	- <u>0.90</u>	
Mi	ineral Metabolism				
5	Phosphoric	1000 - 5	000 2 151	215	

Requisition #:	388366	Physician:	NO PHYSICIAN		
Patient Name:	Natasha Gordon	Date of Collection:	5/25/2015		
Indicator of Fluid Intake					

76 *Creatinine

mg/dL

88

*The creatinine test is performed to adjust metabolic marker results for differences in fluid intake. Urinary creatinine has limited diagnostic value due to variability as a result of recent fluid intake. Samples are rejected if creatinine is below 20 mg/dL unless the client requests results knowing of our rejection criteria.

Explanation of Report Format

The reference ranges for organic acids were established using samples collected from typical individuals of all ages with no known physiological or psychological disorders. The ranges were determined by calculating the mean and standard deviation (SD) and are defined as \pm 2SD of the mean. Reference ranges are age and gender specific, consisting of Male Adult (\geq 13 years), Female Adult (\geq 13 years), Male Child (<13 years), and Female Child (<13 years).


There are two types of graphical representations of patient values found in the new report format of both the standard Organic Acids Test and the Microbial Organic Acids Test.

The first graph will occur when the value of the patient is within the reference (normal) range, defined as the mean plus or minus two standard deviations.

The second graph will occur when the value of the patient exceeds the upper limit of normal. In such cases, the graphical reference range is "shrunk" so that the degree of abnormality can be appreciated at a glance. In this case, the lower limits of normal are not shown, only the upper limit of normal is shown.


In both cases, the value of the patient is given to the left of the graph and is repeated on the graph inside a diamond. If the value is within the normal range, the diamond will be outlined in black. If the value is high or low, the diamond will be outlined in red.

Example of Value Within Reference Range



Requisition #:	388366	Physician:	NO PHYSICIAN
Patient Name:	Natasha Gordon	Date of Collection:	5/25/2015

Neurotransmitter Metabolism Markers



The diagram contains the patient's test results for neurotransmitter metabolites and shows their relationship with key biochemical pathways within the axon terminal of nerve cells. The effect of microbial byproducts on the blockage of the conversion of dopamine to norepinephrine is also indicated.

Requisition #:	388366	Physician:	NO PHYSICIAN
Patient Name:	Natasha Gordon	Date of Collection:	5/25/2015

Interpretation

High yeast/fungal metabolites (Markers 1,2,3,4,5,6,7,8) indicate a yeast/fungal overgrowth of the gastrointestinal tract. Prescription or natural (botanical) anti-fungals, along with supplementation of high potency multi-strain probiotics (20-50 billion cfu's), may reduce yeast/fungal levels.

High 4-hydroxyphenylacetic acid (Marker 15) is associated with small intestinal bacteria overgrowth due to its production by the following Clostridia bacteria: *C. difficile, C. stricklandii, C. lituseburense, C. subterminale, C. putrefaciens,* and *C. propionicum. C. difficile* can be distinguished from the other species by its production of 4-cresol which none of the other species produce. No information on the pathogenicity of the other species producing 4-hydroxyphenylacetic acid is available. It is likely that the phenol 4-hydroxyphenylacetic is an inhibitor of dopamine-beta-hydroxylase and that patients with high values may have elevated dopamine and HVA/VMA ratios. Elevated values are common in celiac disease and cystic fibrosis and have been reported as elevated in jejuna web, transient lactose intolerance, Giardia infection, ileal resection, ileocolic intussusception, septicemia, and projectile vomiting. Treatment with probiotics or antibiotics may be clinically useful.

Extremely elevated levels of at least 100 mmol/mol creatinine are associated with tyrosinemia, which can be due to immature development of enzymes in infants or to genetic deficiencies.

HVA levels below the mean (Marker 33) may indicate lower production of the neurotransmitter dopamine, perhaps due to low dietary intake of the amino acid precursors phenylalanine or tyrosine. Homovanillic acid is a metabolite of the neurotransmitter dopamine. Supplementation with phenylalanine or tyrosine may be beneficial. Enzyme cofactors magnesium, B6 (pyridoxine) or biopterin may also be deficient; neurotransmitter levels may increase with supplementation with these cofactors if these are deficient.

VMA levels below the mean (Marker 34) may indicate lower production of the neurotransmitter norepinephrine or the hormone adrenaline, perhaps due to low dietary intake of the amino acid precursors phenylalanine or tyrosine. Vanylmandelic acid (VMA) is a metabolite of norepinephrine or adrenaline. Low VMA may also result from blocked conversion of dopamine to norepinephrine by *Clostridia* metabolites. Supplementation with phenylalanine or tyrosine may be beneficial. Enzyme cofactors magnesium, B6 (pyridoxine) or biopterin may also be deficient and respond to supplementation.

5-hydroxyindoleacetic acid (**5-HIAA**) **levels below the mean (Marker 36**) may indicate lower production of the neurotransmitter serotonin. 5-hydroxy-indoleacetic acid is a metabolite of serotonin. Low values have been correlated with symptoms of depression. Supplementation with the precursor 5-HTP (5-hydroxytryptophan) at 50-300 mg/day may be beneficial. Supplementation with tryptophan itself may form the neurotoxic metabolite quinolinic acid, however, 5-HTP is not metabolized to quinolinic acid. Excessive tryptophan supplementation has been associated with eosinophilia myalgia syndrome.

Requisition #:	388366	Physician:	NO PHYSICIAN
Patient Name:	Natasha Gordon	Date of Collection:	5/25/2015

High quinolinic acid / 5-HIAA ratio (Marker 39) indicates an imbalance of these organic acids and may be a sign of neural excitotoxicity. Quinolinic acid is an excitotoxic stimulant of certain brain cells that have NMDA-type receptors. Overstimulated nerve cells may die. Brain toxicity due to quinolinic acid has been implicated in Alzheimer's disease, autism, Huntington's disease, stroke, dementia of old age, depression, HIV-associated dementia, and schizophrenia. However, quinolinic acid is derived from the amino acid tryptophan and is an important intermediate that the body uses to make the essential nutritional cofactor nicotinamide adenine dinucleotide (NAD), which can also be derived from niacin (B3).

An elevated ratio is not specific for a particular medical condition and is commonly associated with excessive inflammation due to recurrent infections. If quinolinic acid is not elevated, low 5-HIAA from serotonin may be the source of the imbalance. Supplementation with 5-HTP may increase serotonin levels, but 5-HTP is not metabolized to quinolinic acid. Immune overstimulation, excess adrenal production of cortisol due to stress, or high exposure to phthalates may also increase the quinolinic acid/5-HIAA acid ratio.

The drug deprenyl or the dietary supplements carnitine, melatonin, capsaicin, turmeric (curcumin) and garlic may reduce brain damage caused by quinolinic acid. Niacin (nicotinic acid) and niacinamide may also reduce quinolinic acid production by decreasing tryptophan shunting to the quinolinic acid pathway. Inositol hexaniacinate as an adult dose of 500-1000 mg does not cause niacin flush.

Pyridoxic acid (B6) levels below the mean (Marker 51) may be associated with less than optimum health conditions (low intake, malabsorption, or dysbiosis). Supplementation with B6 (20 - 50 mg/day) or a multivitamin may be beneficial.

Pantothenic acid (B5) levels below the mean (Marker 52) may be associated with less than optimum health conditions. Supplementation with B5 (250 mg/day) or a multivitamin may be beneficial.

Ascorbic acid (vitamin C) levels below the mean (Marker 54) may indicate a less than optimum level of the antioxidant vitamin C. Suggested supplementation is 1000 mg/day of buffered vitamin C, divided into 2-3 doses.

High 2-hydroxyhippuric acid (Marker 61) may result after ingestion of aspartame (Nutrasweet®) or salicylates (aspirin), or from GI bacteria converting tyrosine or phenylalanine to salicylic acid. 2-Hydroxyhippuric acid is a conjugate of hydroxybenzoic acid (salicylic acid) and glycine.

Low citramalic, 2-hydroxyphenylacetic, 4-hydroxyphenylacetic, 4-hydroxybenzoic, 4-hydroxyhippuric, 3-indoleacetic, glyceric, glycolic, oxalic, lactic, pyruvic, 2-hydroxybutyric, fumaric, malic, aconitic, quinolinic, kynurenic, quinolinic/5-HIAA ratio, thymine, ethylmalonic, methylsuccinic, adipic, suberic, glutaric, 3-hydroxy-3-methylglutaric, methylcitric, or orotic values have no known clinical significance.

Low values for amino acid metabolites (Markers 62-74) indicate the absence of genetic disorders of amino acid metabolism. These markers are deamination (ammonia removed) byproducts that are very elevated only when a key enzyme has low activity; slight elevations may indicate a genetic variation or heterozygous condition which may be mitigated with diet or supplementation. Low values are not associated with inadequate protein intake and have not been proven to indicate specific amino acid deficiencies.

High quality nutritional supplements can be purchased through your practitioner or at New Beginnings Nutritionals, <u>www.NBNUS.com < http://www.NBNUS.com></u>, or call 877-575-2467.

Certain uses of the compounds arabinose, citramalic, tartaric, 3-oxoglutaric, carboxycitric, 3,4-dihydroxyphenylpropionic acid and 3-(3-hydroxyphenyl)-3-hydroxypropionic acid in their application to autism in the Organic Acid Test and Microbial Organic Acid Test are protected by USA patent 5,686,311 granted to The Great Plains Laboratory, Inc., November 11, 1997.